Fate Therapeutics reports lower Q4 collaboration revenue

Reuters02-26
Fate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports lower Q4 collaboration revenue

Overview

  • Biopharmaceutical firm's Q4 collaboration revenue fell yr/yr

  • Company reported Q4 net loss of $32.4 mln

  • Operating expenses decreased 30% in 2025 compared to 2024

Outlook

  • Company projects operating runway through year-end 2027 with $205 mln in cash

  • Fate Therapeutics to provide clinical updates in H2 2026

  • Company plans Phase 2 trial in lupus nephritis

Result Drivers

  • OUTPATIENT TREATMENT - FT819 off-the-shelf CAR T-cell therapy enabled outpatient treatment, expanding access and reducing hospital stays

  • CANCER THERAPY SUCCESS - FT836 showed significant tumor reduction in colorectal cancer without conditioning chemotherapy, highlighting early activity

  • COST REDUCTION - Company plans a 30% reduction in operating expenses in 2025 compared to 2024, supporting financial runway through 2027

Company press release: ID:nGNX5WTXcW

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Collaboration Revenue

$1.37 mln

Q4 Net Income

-$32.37 mln

Q4 Basic EPS

-$0.27

Q4 Income from Operations

-$34.72 mln

Q4 Operating Expenses

$36.09 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00, about 237.8% above its February 25 closing price of $1.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment